SAN DIEGO, Sept. 16, 2021 /PRNewswire/ -- Evofem
Biosciences, Inc., (NASDAQ: EVFM) today announced that seven
data sets from clinical trials of Phexxi® (lactic acid, citric acid
and potassium bitartrate) and EVO100 will be presented at four
medical society meetings in October
2021.
"We look forward to providing important clinical insights
related to the robust data supporting Phexxi," said Brandi Howard, PhD, Evofem Biosciences' Head of
Medical Affairs and Lead for the AMPOWER and AMPREVENCE trials.
"There is tremendous interest nationally and internationally from
healthcare providers to learn more about Evofem's vaginal pH
modulator, Phexxi, for contraception and for investigational
EVO100 for protection from certain sexually transmitted infections
including chlamydia and gonorrhea."
The 2021 fall medical society meeting season begins with two
posters at the Society of Family Planning (SFP) Annual
Meeting:
Abstract
Title*:
|
Genitourinary
symptoms by frequency of use of a vaginal pH modulator: Results
from the phase 3 AMPOWER trial
|
Authors:
|
Teresa Becker, MD;
Kelly Culwell, MD, MPH; Clint Dart, MS; Brandon Howard,
PhD
|
Poster
Number:
|
P46
|
Category:
|
Contraception
|
*Evofem's poster was
among the highest scored posters accepted by SFP
and is eligible to receive an award at the conference.
Winners will be announced at the end of the conference.
|
Abstract
Title:
|
Pooled safety data
from two phase 3 trials of a vaginal pH modulator: Results from
AMPOWER and AMP001
|
Authors:
|
Teresia Lee, MD;
Kelly Culwell, MD, MPH; Clint Dart, MS; Brandon Howard,
PhD
|
Poster
Number:
|
P50
|
Category:
|
Contraception
|
Accepted scientific posters will be showcased in a Poster
reception on September 27, 2021, from 6:00pm-7:00pm ET. The SFP virtual Annual
Meeting will be held October 1-2,
2021.
Dr. Howard will present three posters at the American Society
for Reproductive Medicine (ASRM) 77th Scientific Congress &
Expo in Baltimore, Maryland on
Wednesday, October 20, 2021:
Abstract
Title:
|
Timing of On-Study
Pregnancies with a Vaginal pH Modulator in the Phase 3 AMPOWER
Trial (10797)
|
Authors:
|
B. Todd Chappell, MD;
Kelly Culwell, MD, MPH; Clint Dart, MS; Brandon Howard,
PhD
|
Poster
Number:
|
P-436
|
Date:
|
Wednesday, October
20, 2021
|
Poster
Session:
|
Contraception
|
|
|
Abstract
Title:
|
Side effects by
frequency of use with EVO100 vaginal gel: results from the Phase
2B/3 AMPREVENCE trial (10790)
|
Authors:
|
Ronald
Surowitz; Kelly Culwell, MD, MPH; Clint Dart, MS; Brandon
Howard, PhD
|
Poster
Number:
|
P-726
|
Date:
|
Wednesday, October
20, 2021
|
Poster
Session:
|
Public Health and
Reproduction
|
|
|
Abstract
Title:
|
Incorporating
direct patient health outcomes into clinical trials for the
prevention of urogenital chlamydia trachomatis infection: analysis
of a novel endpoint in a clinical trial of
EVO100
|
Authors:
|
John Powers; Kelly
Culwell, MD, MPH; Clint Dart, MS; Brandon Howard, PhD
|
Poster
Number:
|
P-720
|
Date:
|
Wednesday, October
20, 2021
|
Poster
Session:
|
Public Health and
Reproduction
|
These abstracts will be published online in
the Fertility and Sterility Abstract Supplement in
September 2021. Poster abstracts will
also be available in the ASRM On-Demand Congress content.
At AMCP Nexus 2021, B. Todd
Chappell, MD, FACOG, will give an Encore presentation of a
poster detailing results of the Phase 2B/3 AMPREVENCE study. This double-blinded,
placebo-controlled study met its primary and secondary efficacy
endpoints, with statistically significant reductions in the risk of
chlamydia and gonorrhea infections in women.
Abstract
title:
|
Efficacy and
Safety of EVO100 for Prevention of Chlamydia and Gonorrhea: Results
From AMPREVENCE, a Phase 2B/3 Study
|
Authors:
|
B. Todd Chappell, MD;
Scott Mollan, MS, MBA; Kelly Culwell, MD, MPH; Brandon Howard,
PhD
|
Poster
Number:
|
A3
|
Date:
|
Wednesday, October
20
|
Time:
|
12:00 - 2:30pm
MT
|
Dr. Chappell, an obstetrician/gynecologist practicing
at Adams Patterson Gynecology &
Obstetrics in Memphis, Tennessee, was the lead
author of the pivotal AMPREVENCE manuscript which was
published in the American Journal of Obstetrics and
Gynecology (AJOG) in 20211.
Finally, at the International Federation
of Gynecology and Obstetrics (FIGO)
XXIII World Congress of Obstetrics and Gynecology to be
held virtually October 21-28, 2021,
Dr. Howard will present a poster highlighting efficacy of the
contraceptive vaginal gel Phexxi® (lactic acid, citric acid and
potassium bitartrate) when used as directed in the pivotal Phase 3
AMPOWER study.
Abstract
title:
|
Perfect-use
efficacy results with Phexxi® from the Phase 3 AMPOWER
study
|
Authors:
|
B. Todd Chappell, MD;
Kelly Culwell, MD, MPH; Clint Dart, MS; Brandon Howard,
PhD
|
Poster
Number:
|
0610
|
This abstract will be published as a supplement to
FIGO's International Journal of Gynaecology and
Obstetrics.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is developing and commercializing innovative
products and product candidates to address unmet needs in women's
sexual and reproductive health, including hormone-free,
woman-controlled contraception and protection from certain sexually
transmitted infections (chlamydia and gonorrhea). For more
information, please visit evofem.com.
Phexxi® is a registered trademark of Evofem
Biosciences, Inc.
1 Chappell B.T. et al. EVO100
prevents chlamydia and gonorrhea in women at high risk of
infection. American Journal of Obstetrics and Gynecology,
Volume 225, Issue 2, August 2021, Pages 162.e1-162.e14.
https://www.sciencedirect.com/science/article/abs/pii/S0002937821001563
Investor Relations Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
View original content to download
multimedia:https://www.prnewswire.com/news-releases/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator-301378506.html
SOURCE Evofem Biosciences, Inc.